Coherus BioSciences Inc CHRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/03/24 EDT
2.27UNCH (UNCH)
Volume
8,271
Close
2.27quote price arrow up+0.10 (+4.61%)
Volume
1,512,883
52 week range
1.43 - 8.22
Loading...
  • Open2.20
  • Day High2.32
  • Day Low2.19
  • Prev Close2.17
  • 52 Week High8.22
  • 52 Week High Date05/08/23
  • 52 Week Low1.43
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap257.641M
  • Shares Out113.50M
  • 10 Day Average Volume1.39M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-31.83

KEY STATS

  • Open2.20
  • Day High2.32
  • Day Low2.19
  • Prev Close2.17
  • 52 Week High8.22
  • 52 Week High Date05/08/23
  • 52 Week Low1.43
  • 52 Week Low Date11/10/23
  • Market Cap257.641M
  • Shares Out113.50M
  • 10 Day Average Volume1.39M
  • Dividend-
  • Dividend Yield-
  • Beta0.67
  • YTD % Change-31.83

RATIOS/PROFITABILITY

  • EPS (TTM)-2.56
  • P/E (TTM)-0.89
  • Fwd P/E (NTM)-3.16
  • EBITDA (TTM)-189.408M
  • ROE (TTM)-1,657.06%
  • Revenue (TTM)257.244M
  • Gross Margin (TTM)38.19%
  • Net Margin (TTM)-92.48%
  • Debt To Equity (MRQ)-245.28%

EVENTS

  • Earnings Date05/09/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Coherus BioSciences Inc

 

Profile

MORE
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing...
Dennis Lanfear
Chairman of the Board, President, Chief Executive Officer
Bryan Mcmichael
Interim Chief Financial Officer
Address
C/O DENNIS M. LANFEAR
201 REDWOOD SHORES PARKWAY, SUITE 200
Redwood City, CA
94065
United States

Top Peers

SYMBOLLASTCHG%CHG
ME
23andMe Holding Co.
0.5023-0.0023-0.4558%
PBYI
Puma Biotechnology Inc
4.86-0.10-2.02%
RVNC
Revance Therapeutics Inc
3.95+0.18+4.77%
AKBA
Akebia Therapeutics Inc
1.37+0.07+5.38%
XERS
Xeris Biopharma Holdings Inc
1.89+0.03+1.61%